Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carni Q-gel
- Development stage
- Unknown
- Lead developer
- Tishcon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carni Q-gel is a combination nutraceutical/dietary supplement developed by Tishcon Corporation, containing L-carnitine fumarate and hydrosoluble reduced ubiquinol (the active form of Coenzyme Q10). Formulated as a soft-gel capsule to enhance bioavailability, it is used as an adjunctive therapy for patients with chronic heart failure (CHF). The product targets myocardial mitochondrial dysfunction and systemic inflammation by providing essential cofactors for energy metabolism and reducing pro-inflammatory cytokines such as IL-6 and TNF-alpha. Clinical evidence from the randomized, double-blind 'Tishcon Study' indicates that Carni Q-gel improves quality of life and functional capacity, as measured by the six-minute walk test, in heart failure patients receiving standard therapy.
- Brand names
- Carni Q-gel
- Other names
- ubiquinol + L-carnitine fumarate
02
Targets
SLC7A1 (Cationic amino acid transporter 1)IL-6 (Interleukin 6)ND1 (Mitochondrial electron transport chain complex I)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Carni Q-gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carni Q-gel.